Evidence map›Paper›PMID 38310350›Full record

ArticleThe American journal of case reports2024

Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia.

Shivani Sharma, Manasa Morisetti, Nitesh Gandhi, Suma Sri Chennapragada, James D Cotelingam, Poornima Ramadas

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shivani SharmaDepartment of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.ORCID 0009-0003-6605-8045
Manasa MorisettiDepartment of Pathology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Nitesh GandhiDepartment of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Suma Sri ChennapragadaDepartment of Hematology and Oncology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
James D CotelingamDepartment of Pathology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Poornima RamadasDepartment of Hematology and Oncology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Louisiana State University Health Sciences Center Shreveport · USLouisiana State University in Shreveport · USLouisiana State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Three driver mutations have been identified in patients with essential thrombocythemia - JAK2 V617F, CALR, and MPL. Out of these, JAK2 V617F is mostly common. These mutations are thought to be mutually exclusive; therefore, the initial workup may not include the identification of all mutations separately. CASE REPORT We present a case of a 55-year-old woman who was referred to the hematology clinic for an elevated platelet count noted when she was hospitalized for a renal stone. The patient was asymptomatic. A workup was initiated for essential thrombocythemia, and she was tested for JAK2 V617F mutation using an allele-specific polymerase chain reaction (AS-PCR) test in peripheral blood, which came back positive. The variant allele frequency was 2%. She underwent a bone marrow biopsy, and next-generation sequencing (NGS) showed a CALR mutation. A 52 bp deletion-type mutation was detected in the CALR gene on exon 9, with a variant allele frequency of 7%. The NGS did not detect JAK2 mutation due to its low sensitivity. She was started on aspirin alone as she was less than 60 years old and had no history of thrombotic events. The patient has been following up with the hematology clinic for the last 2 years and has not had any thrombotic events. CONCLUSIONS We propose that in patients with a low JAK2 V617 allele variant, testing for other driver mutations should be performed. In our patient, JAK2 mutation could be clonal hematopoiesis of indeterminate potential; therefore, the dominant mutation (CALR) would determine the disease phenotype.

Indexed as

Thrombocythemia, EssentialThrombosisExonsFemaleHumansJanus Kinase 2Middle AgedMutationPolymerase Chain ReactionJanus Kinase 2

Identifiers

PMID38310350
PMCPMC10858393
OpenAlexW4390450499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.